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for clinical characteristics, Xience stent utilization was no longer associated with
improved outcome.
Conclusion: The use of Xience in routine clinical practice is both safe and effective
and has borderline clinical advantage over first-generation stents.
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Background: Drug eluting stents (DES) have been shown to significantly decrease
restenosis with subsequent need for lesion and/or vessel revascularization when
compared with bare metal stents (BMS) in selected patient groups in randomized trials
and in observational registries. If their use in all-comers is also associated with a
survival benefit over a longer follow-up is controversial.
Methods: We used the Myocardial Infarction Data Acquisition System (MIDAS), a
New Jersey statewide database, to examine the mortality of 37,812 patients (pts) who
underwent PCI (emergent or elective) with a single stent, either BMS (n=14,939) or
DES (n=22,873) from 2003 to 2004, with follow-up of 60 months.
Results: The total mortality and the cardiovascular death were significantly lower
(13.63% vs. 18.67%; p<0.0001), and (5.85% vs. 9.17%; p<0.0001) respectively among
patients who received DES compared to BMS. After adjusting for baseline
characteristcs such as age, sex, race, diabetes, hypertension, renal disease, anemia,
cancer, cerebrovascular disease and left ventricular dysfunction the benefits associated
with DES persisted; the hazard ratios for total mortality and cardiovascular mortality
were 0.78 (95% CI 0.73 to 0.89; p<0.0001) and 0.77 (95% CI 0.67 to 0.89; p=0.0004)
respectively.
Conclusion: In this population based observational study, patients who received DES
had significantly lower 5 year total and cardiovascular mortality than those who
received BMS.
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Background: Previous studies have demonstrated the potential utility of the age,
creatinine, and ejection fraction (ACEF) score [age/(left ventricular ejection fraction
+ 1, if creatinine > 2.0 mg/dL)] to assess the risk of mortality and myocardial infarction
(MI) 1 year after percutaneous coronary intervention (PCI). However, this score has
not been extensively validated in patients undergoing PCI in routine clinical practice.
Therefore, we sought to investigate if the ACEF score would predict adverse events in
patients undergoing contemporary PCI.
Methods: A total of 2779 patients, who received at least one stent during PCI and of
whom data was available to calculate the ACEF score, were selected from Waves 4
(2004) and 5 (2006) of the NHLBI Dynamic Registry. The in-hospital and 3-year
outcomes (mortality and MI) were prospectively collected and stratified according to
the ACEF score tertiles.
Results: The ACEF terciles were as follow: LOW <1.0477, 1.0477≤ MID <1.3819,
and HIGH ≥1.3819. An increasing trend in ACEF score was associated with increases
in inhospital mortality (LOW = 0%, MID = 0.4%, HIGH = 2%; ptrend <0.0001).
Similarly, HIGH had the highest mortality at 3-year follow-up (figure). After
adjustment for confounding variables, the relationship between high ACEF score and
mortality at 3 years remained statistically significant.
3-year cumulative mortality by ACEF tercile.
Conclusion: The ACEF score may serve as a risk assessment tool for mortality after
PCI. Future studies are needed to better determine the use of ACEF score in routine
clinical practice.
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Background: The SYNTAX trial was designed to compare percutaneous coronary
intervention (PCI) with paclitaxel-eluting TAXUS Express stents versus coronary
artery bypass surgery (CABG) for the treatment of 3-vessel (3VD) and/or left main
coronary disease (LM). This analysis compares outcomes at 4 years.
Methods: SYNTAX is a randomized clinical trial with nested registries. A cardiac
surgeon and interventional cardiologist screened consecutive patients with de novo
3VD and/or LM disease. The patient was randomized if amenable for equivalent
revascularization with both treatments; otherwise, they were enrolled in a nested
registry.
Results: At 1 year, MACCE and repeat revascularization were significantly higher in
the PCI group. The rate of death/stroke/MI was similar between groups. After 3 years
of follow-up, MACCE, repeat revascularization, MI and cardiac death were
significantly increased in the PCI arm (Table). Death/stroke/MI and stroke were similar
between the groups at 3 years (Table). MACCE at 3-years was similar between
treatment arms in patients with low/intermediate SYNTAX Scores but significantly
increased in PCI patients with high SYNTAX Scores. The full 4 year results will be
available at the time of presentation.
Conclusion: This will be the first presentation of 4-year outcomes in the randomized
SYNTAX patient population. Three-year results suggest that CABG remains the
standard of care for patients with complex lesions (high SYNTAX Score). With less
complex disease (low/intermediate SYNTAX Scores), PCI may be an acceptable
revascularization alternative.
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